Dexdor: a new hospital-only sedative

Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY
Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY

Dexdor (dexmedetomidine) is licensed for adult patients in intensive care who require sedation not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Dexmedetomidine is a selective alpha-2 receptor agonist. It exerts its sedative effect through decreased firing of the locus coeruleus, the predominant noradrenergic nucleus in the brainstem. Dexmedetomidine has minimal respiratory depressive effects.

Dexdor must be given by intravenous infusion using a controlled infusion device.

View Dexdor drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

First body-identical combination HRT launched

First body-identical combination HRT launched

Bijuve is a combination of estradiol and progesterone,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...